newsnews.ai

Engineered Blood Clots Stop Severe Bleeding in Seconds

Researchers have developed a 'click clotting' technique that creates tougher, faster-forming blood clots to prevent life-threatening hemorrhage.

By NewsNews AI
This is an image of a blood clot taken using an inverted fluorescent confocal microscope (Zeiss LSM710). Blood clots are made up of blood cells called platelets and a protein called fibrin which adher
This is an image of a blood clot taken using an inverted fluorescent confocal microscope (Zeiss LSM710). Blood clots are made up of blood cells called platelets and a protein called fibrin which adher·Photo: Joanne Mitchell via Wikimedia Commonscc-by-sa

Rapid Hemostasis Technology

Researchers have developed a method to create engineered blood clots (EBCs) that can stop bleeding in seconds, significantly faster than the natural coagulation process. While natural blood clots are essential for regeneration and stopping blood loss, they are often mechanically fragile and slow to form, which can lead to life-threatening hemorrhages.

According to the research team, the current natural clotting process can take between one and five minutes in some situations. In contrast, the synthetic application works "almost instantaneously" to form a clot. In animal trials involving severe liver wounds in rats, the engineered treatment stopped bleeding in less than five seconds, compared to 265 seconds in untreated subjects.

The 'Click Clotting' Mechanism

The technique, described as "click clotting," involves rapidly crosslinking red blood cells into tough cytogels that integrate within blood clots. The researchers achieved this by separating the cellular components of the blood and adding chemicals that act as "handles". One side of these handles attaches to proteins on the surface of red blood cells, while the other side links with a long-chain molecule that binds the cells together.

Once modified, these cells are returned to the plasma and injected into the wound. This strategy is designed to overcome the limitations of natural clots, which the researchers attribute to complex coagulation cascades and a lack of structural polymers.

Mechanical Improvements

The resulting engineered blood clots exhibit significant mechanical advantages over native clots. Specifically, the EBCs show a 13-fold increase in fracture toughness and a 4-fold improvement in adhesion energy.

The research team noted that this approach is advantageous over previous methods that used chitosan to crosslink red blood cells. According to the team, chitosan-based methods often resulted in inconsistent clotting, hemolysis, or the creation of brittle clots.

Potential for Regeneration

Beyond the immediate cessation of bleeding, the technology may assist in the healing process. A researcher from McGill University stated that because the technology utilizes the body's own blood, it can help promote regeneration. He described the development as a "life-saving kind of technology" due to its ability to quickly stop bleeding while supporting the body's natural recovery mechanisms.

Sources (7)Open

Topics

How NewsNews AI made this storyOpen

NewsNews AI researched this story across 7 sources, drafted it, and ran the result through an independent editorial pass. It cleared editorial review on first pass.

  • 7 sources cited · linked in full at the bottom of the article
  • Image license verified · cc-by-sa
  • Independent editorial pass · approved

From the editor

All key factual claims are supported by their cited snippets: the 13-fold fracture toughness and 4-fold adhesion energy improvements are confirmed by source [2]; the <5 seconds vs. 265 seconds rat liver wound data is confirmed by source [5]; the chitosan comparison is confirmed by source [2]; the 1–5 minute natural clotting time and "almost instantaneously" quote are confirmed by source [4]; and the mechanical fragility/slow formation framing is confirmed by source [3]. Source [1] has no snippet but is cited only alongside [4] for a general claim also supported by [4]. No fabricated quotes, no single-source dependency, and the headline accurately reflects the content.

More about our editorial process

Feedback

We want to hear from you, especially when something is wrong. No signup, no email required.

Keep reading